Lanthanum carbonate for hyperphosphatemia in patients with advanced CKD and patients receiving dialysis

References

• Albaaj F, Hutchison AJ. Lanthanum carbonate for the treatment of hyperphosphataemia in renal failure and dialysis patients. Expert Opin. Pharmacother.6(2), 319–328 (2005).
   PubMed Web of Science ®Google Scholar
• Block GA. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol.15, 2208–2218 (2004).
   PubMed Web of Science ®Google Scholar
• Block GA, Hulbert-Shearon TE, Levin NW, Port FK. Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: a national study. Am. J. Kidney Dis.31, 607–617 (1998).
   PubMed Web of Science ®Google Scholar
• Davies MR, Hruska KA. Pathophysiological mechanisms of vascular calcification in end-stage renal disease. Kidney Int.60(2), 472–479 (2001).
   PubMedGoogle Scholar
• Melamed ML, Eustace JA, Plantinga L et al. Changes in serum calcium, phosphate and PTH and the risk of death in incident dialysis patients: a longitudinal study. Kidney Int.70(2), 351–357 (2006).
   PubMed Web of Science ®Google Scholar
• Block GA, Port FK. Re-evaluation of risks associated with hyperphosphatemia and hyperparathyroidism in dialysis patients: recommendations for a change in management. Am. J. Kidney Dis.35, 1226–1237 (2000).
   PubMed Web of Science ®Google Scholar
• Isakova T, Gutiérrez OM, Chang Y et al. Phosphorus binders and survival on hemodialysis. J. Am. Soc. Nephrol.20, 388–396 (2009).
   PubMed Web of Science ®Google Scholar
• National Kidney Foundation. K/DOQI clinical practice guidelines: bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis.42, S1–S201 (2003).
   PubMedGoogle Scholar
• The Renal Association. UK Renal Registry, Eighth Annual Report. 39–41 (2005).
   Google Scholar
• Walton J, Gray TK. Absorption of inorganic phosphate in the human small intestine. Clin. Sci. Mol. Med.56, 407 (1979).
   Google Scholar
• Damment SJ, Pennick M. Clinical pharmacokinetics of the phosphate binder lanthanum carbonate. Clin. Pharmacokinet.47(9), 553–563 (2008)
   PubMed Web of Science ®Google Scholar
• Damment SJP, Webster I. The pharmacology of lanthanum carbonate (Fosrenal): a novel non-aluminium, non-calcium phosphate binder. Presented at: 36th Annual Meeting of the American Society of Nephrology. San Diego, CA, USA 14–17 November 2003.
   Google Scholar
• Molony DA, Murthy B. Accumulation of metals and minerals from phosphate binders. Blood Purif.23(Suppl. 1), 2–11 (2005).
   PubMed Web of Science ®Google Scholar
• Cannata-Andia JB, Fernandez-Martin JL. The clinical impact of aluminium overload in renal failure. Nephrol. Dial. Transplant.17(Suppl. 2), 9–12 (2002).
   PubMedGoogle Scholar
• Slatopolsky E, Weerts C, Norwood K et al. Long-term effects of calcium carbonate and 2.5mEq/litre calcium dialysate on mineral metabolism. Kidney Int.36, 897–903 (1989).
   PubMed Web of Science ®Google Scholar
• Goodman WG, Goldin J, Kuizon BD. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med.342, 1478–1483 (2000).
   PubMed Web of Science ®Google Scholar
• Braunlin W, Zhorov E, Guo A et al. Bile acid binding to sevelamer HCl. Kidney Int.62, 611–619 (2002).
   PubMed Web of Science ®Google Scholar
• Wanner C, Krane V, Marz W et al. Atorvastatin in patients with Type 2 diabetes mellitus undergoing haemodilaysis. N. Engl. J. Med.353, 238–248 (2005).
   PubMed Web of Science ®Google Scholar
• Chertow GM, Burke SK, Raggi P. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int.62, 245–252 (2002).
   PubMed Web of Science ®Google Scholar
• Block GA, Spiegel DM, Ehrlich J et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to haemodialysis. Kidney Int.68, 1815–1824 (2005).
   PubMed Web of Science ®Google Scholar
• Suki WA, Zabaneh R, Cangiano JL et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int.72, 1130–1137 (2007).
   PubMed Web of Science ®Google Scholar
• Manns B, Klarenbach S, Lee H et al. Economic evaluation of sevelamer in patients with end-stage renal disease. Nephrol. Dial. Transplant.22(10), 2867–2878 (2007).
   PubMed Web of Science ®Google Scholar
• Joy MS, Finn WF. Randomized, double-blind, placebo-controlled, dose-titration, Phase III study assessing the efficacy and tolerability of lanthanum carbonate: a new phosphate binder for the treatment of hyperphosphatemia. Am. J. Kidney Dis.42(1), 96–107 (2003).
   PubMed Web of Science ®Google Scholar
• Hutchison A, Webster I, Gill M et al; on behalf of the 301 Study Group. Long-term safety, tolerability and efficacy of lanthanum carbonate: results for up to 6 years of treatment. Nephron110(1), c15–c23 (2008).
   Google Scholar
• Malluche HH, Faugere MC, Wang G et al. No evidence of osteomalacia in dialysis patients treated with lanthanum carbonate up to 5 years. J. Am. Soc. Nephrol.15, 270A (2004).
   Google Scholar
• Drueke TB. Risks related to metal absorption. Proceedings of a round table meeting held at the ASN/ISN World Nephrology Convention. Nephrol. Dial. Transplant.17, (2002).
   Google Scholar
• King RO, Fricker SP. Rare earth phosphate binders. JMPC Monthly Report, March (1997).
   Google Scholar
• Finn WF, Joy MS, Hladik G; the Lanthanum study group. Efficacy and safety of lanthanum carbonate for reduction of serum phosphorus in patients with chronic renal failure receiving hemodilaysis. Clin. Neph.62(3), 193–202 (2004).
   PubMed Web of Science ®Google Scholar
• Hutchinson AJ. Improving phosphate-binder therapy as a way forward. Nephrol. Dial. Transplant.19(Suppl. 1), i19–i24 (2004).
   Google Scholar
• Finn WF, Joy MS, Hladik G et al. Results of a nonrandomized dose-ranging, placebo controlled study of lanthanum carbonate for reduction of serum phosphate in chronic renal failure patients receiving hemodialysis (abstract). Presented at: American Society of Nephrology. Miami, FL, USA, November 1999.
   Google Scholar
• Pennick M, Dennis K, Damment SJP. Absolute bioavailability and disposition of lanthanum in healthy human subjects administered lanthanum carbonate. J. Clin. Pharmacol.46(7), 738–746 (2006).
   PubMed Web of Science ®Google Scholar
• Damment SJP, Pennick M. Systemic lanthanum is excreted in the bile of rats. Toxicol. Lett.171, 69–77 (2007).
   PubMed Web of Science ®Google Scholar
• Jones C et al. Presented at: 19th European Renal Association–European Dialysis and Trasplant Association Meeting, Lisbon, Portugal 15–18 May 2004.
   Google Scholar
• Damment SJP et al. Stringent contamination control is needed in tissue-deposition studies with lanthanum carbonate. Presented at: National Kidney Foundation Spring Clinical Meeting Chicago, IL, USA 19–23 April 2006.
   Google Scholar
• Autissier V, Damment SJP, Henderson R. Influence of bile acids on the phosphate-binding efficacy of lanthanum carboante and sevelamer hydrochloride. Presented at: 38th Annual Meeting of the American Society of Nephrology, Philadelphia, PA, USA 8–13 November 2005.
   Google Scholar
• Fiddler G, Taubel J. Lanthanum carbonate does not affect the pharmacokinetics of concomitant treatment with digoxin. Am. J. Kidney Dis.41(4), A18 (2003) (Abstract 26).
   PubMedGoogle Scholar
• Fiddler G, Taubel J. No pharmacokinetic interaction between lanthanum carbonate and metoprolol. Am. J. Kidney Dis.41(4), A18 (2003) (Abstract 27).
   PubMedGoogle Scholar
• Fiddler G, Webster I. Lanthanum carbonate does not affect the pharmacokinetics of concomitant treatment with warfarin. Am. J. Kidney Dis.41(4), A18 (2003) (Abstract 25).
   PubMedGoogle Scholar
• Radandt JM, Marchbanks CR, Dudley MN. Interactions of fluoroquinolones with other drugs: mechanisms, variability, clinical significance, and management. Clin. Infect. Dis.14, 272–284 (1992).
   PubMed Web of Science ®Google Scholar
• Frost RW, Lasseter KC, Noe AJ et al. Effects of aluminium hydroxide and calcium carbonate antacids on the bioavailability of ciprofloxacin. Antimicrob. Agents Chemother.36, 830–832 (1992).
   PubMed Web of Science ®Google Scholar
• Sahai J, Healy DP, Stotka J et al. The influence of chronic administration of calcium carbonate on the bioavailability of oral ciprofloxacin. Br. J. Clin. Pharmacol.35, 302–304 (1993).
   PubMedGoogle Scholar
• How PP, Fischer JH, Arruda JA et al. Effects of lanthanum carbonate on the absorption and oral bioavailability of ciprofloxacin. Clin. J. Am. Soc. Nephrol.2, 1235–1240 (2007).
   PubMed Web of Science ®Google Scholar
• Finn WF, Joy MS, Hladik G et al. Results of a randomized dose-ranging, placebo controlled study of lanthanum carbonate for reduction of serum phosphate in chronic renal failure patients receiving hemodialysis (abstract). Presented at: American Society of Nephrology. Miami, FL, USA 1–8 November 1999.
   Google Scholar
• Hutchison A, Webster I, Gill M, Schmieder R; on behalf of the 301 Study Group. Safety, tolerability and efficacy of lanthanum carbonate in haemodialysis patients: a 12 month study. Presented at: 40th ERA–EDTA World Congress of Nephrology. Berlin, Germany, 8–12 June 2003.
   Google Scholar
• D’Hease PC, Spasovski GB, Sikole A et al. A multicenter study on the effects of lanthanum carbonate (FOSRENOL™) and calcium carbonate on the renal bone disease in dialysis patients. Kidney Int.63(Suppl. 85), S73–S78 (2003).
   Google Scholar
• Hutchison AJ, Speake M, Albaaj F. Reducing high phosphate levels in patients with chronic renal failure undergoing dialysis: a 4-week, dose-finding, open-label study with lanthanum carbonate. Nephrol. Dial. Transplant.19, 1902–1906 (2004).
   PubMed Web of Science ®Google Scholar
• Behets GJ, Verberckmoes SC, Oste L et al. Localization of lanthanum in bone of chronic renal failure rats after oral dosing with lanthanum carbonate. Kidney Int.67, 1830–1836 (2005).
   PubMed Web of Science ®Google Scholar
• Spasovski GB, Sikole A, Gelev S et al. Evolution of bone and plasma concentration of lanthanum in dialysis patients before, during 1 year of treatment with lanthanum carbonate and after 2 years of follow-up. Nephrol. Dial. Transplant.21, 2217–2224 (2006).
   PubMed Web of Science ®Google Scholar
• Finn WF. Lanthanum carbonate vs. standard therapy in hyperphosphataemia: interim findings from a 2 year safety and outcomes study. Presented at: 36th Annual Meeting and Scientific Exposition of the American Society of Nephrology. San Diego, USA, 14–17 November 2003.
   Google Scholar
• Finn WF; on behalf of the 307 Study Group. Lanthanum carbonate versus standard therapy for the treatment of hyperphosphatemia: safety and efficacy in chronic maintenance hemodialysis patients. Clin. Nephrol.65, 191–202 (2006).
   PubMed Web of Science ®Google Scholar
• Altman P, Barnett ME, Finn WF; on behalf of the SPD405–307 study group. Lanthanum Carbonate Study Group. Cognitive function in stage 5 kidney disease patients on hemodilaysis: no adverse effects of lanthanum carbonate compared with standard phosphate-binder therapy. Kidney Int.71, 252–259 (2007).
   PubMedGoogle Scholar
• Lacour B, Lucas A, Auchère D et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int.67(3), 1062–1069 (2005).
   PubMed Web of Science ®Google Scholar
• Damment SJP, Beavers C, Gatehouse DG. Evaluation of the potential genotoxicity of the phosphate binder lanthanum carbonate. Mutagenesis20(1), 29–37 (2005).
   PubMed Web of Science ®Google Scholar
• Tomasello S, Dhupar S, Sherman RA. Phosphate binders, K/DOQI guidelines, and compliance: the unfortunate reality. Dial. Transpl.33, 236–242 (2004).
   Google Scholar
• Riley S. Patient perceptions of phosphate binders – results of a patient questionnaire. Shire Data on file. 08.2589. Source: Market Research, Insight International, December 2001–January 2002.
   Google Scholar
• Albaaj F, Hutchison AJ. Phosphate control in renal disease. Eur. Renal Dis.1, 30–34 (2007).
   Google Scholar
• Ferreira A, Frazão JM, Monier-Faugere MC; Sevelamer Study Group. Effects of sevelamer hydrochloride and calcium carbonate on renal osteodystrophy in hemodialysis patients. J. Am. Soc. Nephrol.19(2), 405–412 (2008).
   PubMed Web of Science ®Google Scholar
• McIntyre C. New developments in the management of hyperphosphatemia in chronic kidney disease. Semin. Dial.20(4), 337–341 (2007).
   PubMedGoogle Scholar
• Rottembourg JB, Launay-Vacher V, Massard J. Thrombocytopenia induced by nicotinamide in hemodialysis patients. Kidney Int.68, 2911–2912 (2005).
   PubMedGoogle Scholar